We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+43.96%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$148M
AUM Growth
Cap. Flow
+$138M
Cap. Flow %
93.63%
Top 10 Hldgs %
68.44%
Holding
85
New
85
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GLUE icon
76
Monte Rosa Therapeutics
GLUE
$1.35B
$62.7K 0.04%
+4,000
New +$53.9K
TRAW icon
77
Traws Pharma
TRAW
$8.1M
$55.7K 0.04%
+49,260
New +$110K
ATXS
78
DELISTED
Astria Therapeutics
ATXS
$52.4K 0.04%
+4,000
New +$47.8K
EWTX icon
79
Edgewise Therapeutics
EWTX
$4.73B
$49.6K 0.03%
+2,000
New +$40.1K
VTGN icon
80
VistaGen Therapeutics
VTGN
$12.8M
$41.5K 0.03%
+62,701
New +$226K
ENTA icon
81
Enanta Pharmaceuticals
ENTA
$400M
$35.8K 0.02%
+2,270
New +$28.8K
CGEM icon
82
Cullinan Oncology
CGEM
$1.14B
$31.1K 0.02%
+3,000
New +$27.1K
GBIO
83
DELISTED
Generation Bio
GBIO
$30.5K 0.02%
+5,376
New +$30.4K
ELDN icon
84
Eledon Pharmaceuticals
ELDN
$285M
$9.06K 0.01%
+6,000
New +$14.3K
VIR icon
85
Vir Biotechnology
VIR
$1.49B
$1.21K ﹤0.01%
+200
New +$1.19K

Similar funds

Seven Fleet Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Seven Fleet Capital Management, which disclosed 85 positions worth $148M. Its ten largest holdings account for 68% of the portfolio.

Its largest position is CG Oncology: 1,515,151 shares worth $62.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Seven Fleet Capital Management's largest Q4 2025 buy was CG Oncology: 1,515,151 shares worth $62.9M.
  • Seven Fleet Capital Management's ten largest holdings make up 68% of its $148M portfolio in Q4 2025.
  • Seven Fleet Capital Management disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on Seven Fleet Capital Management's 13F filing for Q4 2025, filed 26 Feb 2026.